Eli Lilly and Company broke ground in Houston, Texas, one of ten U.S. manufacturing sites — and fifth location to produce domestic active pharmaceutical ingredients (API) — announced since 2020. As part of the company's $50 billion push to reshore medicine production to meet growing demand at home and export American-made medicines to people around the world, the $6.5 billion Houston site will manufacture Foundayo (orforglipron), Lilly's first synthetic oral GLP-1 medicine, along with other small-molecule medicines and advanced therapeutics.
David A. Ricks, Lilly Chair and CEO: "We are thrilled to break ground on our latest 'medicines made in America' site in the great state of Texas. This $6.5B investment will help change the game for tens of millions of people suffering from overweight, obesity and its consequences like diabetes. We will make and ship Lilly's latest products from Texas to people here at home and around the world."
Lilly is currently hiring in Houston and expects the new facility to create more than 600 high-wage jobs like engineers, scientists, operations personnel, and lab technicians — along with 4,000 construction jobs as the site is being built and brought online. Visit the Lilly Houston career page for open positions or join Lilly's talent community for future opportunities.